[绝经后接受激素替代疗法治疗的女性血浆中纤溶酶原激活物抑制剂（PAI-1）的活性]

[Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy].

作者信息

Ciepłuch R, Czestochowska E

机构信息

Oddziału ginekologii i połoznictwa Szpitala Miejskiego im. Brudzyńskiego w Gdyni.

出版信息

Pol Tyg Lek. 1995 Sep;50(36-39):13-5.

PMID:8650021

Abstract

Prospective studies that included 48 postmenopausal women on hormonal replacement therapy (transdermal estradiol and medroxyprogesterone acetate orally) was performed. Plasma activity of plasminogen activator inhibitor (PAI-1), levels of fibrinogen and serum lipids profile was measured before, after 6 and 12 months of continuous treatment. Plasma activity of PAI-1 showed significant decrease after 6 month of therapy. Plasma fibrinogen concentration significantly decreased (p < 0.05) after 12 months of treatment (271.27 +/- 71.08 vs. 238.33 +/- 34.48 mg/dl).

摘要

开展了一项前瞻性研究，纳入48名接受激素替代疗法（经皮雌二醇和口服醋酸甲羟孕酮）的绝经后女性。在连续治疗6个月和12个月之前、之后，测量纤溶酶原激活物抑制剂（PAI-1）的血浆活性、纤维蛋白原水平和血清脂质谱。治疗6个月后，PAI-1的血浆活性显著降低。治疗12个月后，血浆纤维蛋白原浓度显著降低（p < 0.05）（271.27 +/- 71.08 vs. 238.33 +/- 34.48 mg/dl）。